<DOC>
	<DOCNO>NCT01349881</DOCNO>
	<brief_summary>The investigator hypothesize combination eflornithine sulindac effective reduce three-year event rate adenoma second primary colorectal cancer patient previously treat Stages 0 III colon cancer .</brief_summary>
	<brief_title>S0820 , Adenoma Second Primary Prevention Trial</brief_title>
	<detailed_description>The purpose study ass whether eflornithine 500 mg sulindac 150 mg effective reduce 3-year event rate high risk adenoma second primary colorectal cancer Stage 0 , I II III colon cancer patient . The primary hypothesis test main effect agent , well comparison placebo alone combination sulindac eflornithine .</detailed_description>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>History Stage 0III colon rectal cancer primary resection 1 year previously Postoperative colonoscopy CT scan chest , abdomen &amp; pelvis show evidence disease Must cardiovascular risk factor include unstable angina , history myocardial infarction , cerebrovascular accident , coronary artery bypass surgery , NY Heart Assoc Class III IV heart failure . Patients must know uncontrolled hyperlipidemia ( define LDLC &gt; /= 190 mg/dL triglyceride &gt; /= 500 mg/dL within past 3 year uncontrolled high blood pressure ( systolic blood pressure &gt; 150 mm Hg ) within 28 day prior registration At least 30 day completion adjuvant chemo RT . Presence gastroesophageal reflux disease acceptable control medication Not receive plan receive concomitant corticosteroid , nonsteroidal antiinflammatory drug ( NSAIDs ) , anticoagulant . Maximum aspirin dose 100 mg per day ≤ two 325 mg tablet per week . Able swallow oral medication Laboratory : WBC ≥ 4.0 x 103/mcL , platelet ≥ 100,000/mcL hemoglobin &gt; 11.0 g/dL . Serum bilirubin ≤ 2.0 mg/dL AST ( SGOT ) ALT ( SGPT ) ≤ 2 x IULN . Serum creatinine ≤ 1.5 x IULN Zubrod PS 01 , 18 year age old Will participate clinical trial treatment prevention cancer unless protocol treatment , followup phase Offered opportunity participate blood specimen bank History colon resection &gt; 40 cm Midlow rectal cancer Recurrent metastatic disease High cardiovascular risk ; Uncontrolled hypertension Planned radiation therapy additional chemotherapy Documented history gastric/duodenal ulcer within last 12 month and/or current treatment active symptom gastric/duodenal ulcer Known history familial adenomatous polyposis , hereditary nonpolyposis colorectal cancer , inflammatory bowel disease ≥ 30 dB uncorrectable hearing loss age five tested frequency prestudy audiogram Known hypersensitivity sulindac excipient byproduct . Previous asthma , urticaria , allergictype reaction aspirin NSAIDs Significant medical psychiatric condition would preclude study completion ( 8 year ) No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree &gt; 5 year Pregnant nursing woman . Women/men reproductive potential must agree use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Eflornithine/sulindac prevention trial</keyword>
</DOC>